Monthly Archives: November 2020

When COVID-19 began ravaging federal prisons in New Mexico earlier this year, Gov. Michelle Lujan Grisham chastised the federal government, saying private companies hired to run the facilities weren't doing enough to quell the spread of the illness.

Throughout most of the spring and summer, state-run prisons seemed to be doing a better job of beating back the virus. The number of state prisoners who tested positive for the novel coronavirus remained low.

In recent weeks, however, the virus has made inroads in all 11 state prisons from Roswell to Grants, infecting hundreds of inmates and staff.

Corrections Department spokesman Eric Harrison said the outbreaks were inevitable, given the steep spike in virus cases throughout New Mexico in recent weeks. The department is doing everything possible to ensure the safety of workers and prisoners, he added.

But civil rights advocates, former prison workers and inmates say the governor and Corrections Secretary Alisha Tafoya Lucero should be doing more to reduce the number of infections.

The Central New Mexico Correctional Facility in Los Lunas where all incoming prisoners are screened for placement had about 180 confirmed cases late last week; the Roswell Correctional Center had 218, a number that has exploded since the state reported the facility's first inmate case Nov. 1.

Eight inmates systemwide were hospitalized with COVID-19 last week, Harrison said, and more than 220 staff members had infections.

The state reported Friday (Nov. 13) that a man in his 50s who had been incarcerated at the Northwest New Mexico Correctional Center in Cibola County had died. The death marks the seventh fatality in a state prison, according to Corrections Department data.

"This is exactly what we knew was going to happen and have been trying to prevent," said Lalita Moskowitz, an attorney with the American Civil Liberties Union of New Mexico. "Now it feels like the governor and the Corrections Department should be taking a look at this and making changes, but that's not happening."

A spokeswoman for the governor didn't respond specifically to questions about what the state has learned about controlling the virus in prisons and what it might be doing differently eight months into the pandemic to prevent outbreaks.

Nora Meyers Sackett said the governor is "evaluating all manner of recommendations from public health experts and the state medical advisory team" about how to encourage compliance with best practices "and stem the tide of infections."

A plea for protections

The ACLU of New Mexico has been pushing since the early weeks of the pandemic for a mass release of low-level offenders to reduce inmate populations.

Lujan Grisham instead ordered the rolling release of a narrow class of inmates most of whom were within 30 days of completing their sentences. As of Nov. 10, her order had resulted in the early release of 249 people over a six-month period, and the statewide prison population remained at just over 6,100.

Earlier this year, the ACLU, the state Law Offices of the Public Defender and the New Mexico Criminal Defense Lawyers Association filed a joint petition asking the state Supreme Court to order the governor and corrections secretary to authorize a mass release of inmates. But the court denied the request.

The ACLU and the defense attorneys association then filed a class-action lawsuit against Lujan Grisham and Tafoya Lucero in August on behalf of eight inmates claiming prisons are failing to follow COVID-19 safety policies.

State District Judge Matthew Wilson dismissed the complaint Oct. 20 after state officials argued the plaintiffs hadn't exhausted administrative grievance procedures.

The plaintiffs have appealed Wilson's ruling, arguing the grievance procedure is "unavailable and futile."

"The process is designed to prevent inmates from being heard," Moskowitz said. "We are really seeing the flaws in the system right now."

Inmates' complaints

Individual inmates also have filed lawsuits asking to be released to increase their chances of avoiding the virus.

Ruben Jaramillo a 46-year-old inmate at the Penitentiary of New Mexico near Santa Fe who is serving an 18-year sentence on a drug-trafficking charge filed a lawsuit in state District Court in July asking to be released on a temporary furlough because of medical conditions he has that increase his chances of becoming seriously ill if he contracts the virus.

He said in his handwritten plea that prisoners were issued only one mask each and "were given watered down cleaning solution and no cleaning rags" to keep their living quarters clean. Some staff members, he wrote, "refuse to use masks while at work."

When Jaramillo filed his complaint three months ago, there was only one case among inmates at the Penitentiary of New Mexico. As of Friday, there were 70.

Anthony Oveide, an inmate at the Central New Mexico Correctional Facility, filed a complaint in U.S. District Court in September alleging prisoners at the Los Lunas facility were "on lockdown 24 hours per day, seven days per week."

"We inmates have been stuck in this quarantine unit for over two weeks not knowing anything about what is going on with us," he wrote.

Pushed to resign

Two longtime employees of the Los Lunas prison said in recent interviews they quit their jobs because of fears about the virus and poor treatment from prison officials.

"I didn't want to risk getting COVID and potentially dying from it at the prison," said Ernie Garcia, 43, of Socorro, who had been working in the watchtower at the prison for nearly 20 years when he quit in October.

Garcia said prison officials were slow to adopt virus safety protocols in the first weeks of the pandemic. Eventually, he said, each guard was issued one mask made from an old prison uniform.

"When we asked about extras, they said, 'Just take a shower when you get home. When you are in the shower, wash it, like the inmates do their laundry, and when you wake up and come back to work, it should be dry,' " Garcia said.

The Corrections Department eventually gave one disposable N95 mask to each officer, he said, and they were asked to then turn them in after two weeks of use so they could be disinfected and reused.

Officials at the Los Lunas prison sent an email to staff Nov. 3 saying if they needed a new mask, it would be a "1 for 1 exchange."

"We are limited on stock," the email said, "so please use your best judgement on replacing."

Harrison said, however, that each inmate was given three reusable face masks, and employees were issued "N95s, disposable surgical masks, as well as cloth masks."

The department is "strictly following [Centers for Disease Control and Prevention] guidelines on decontamination and reuse for N95 respirator masks," Harrison said.

Garcia said a series of events that led him to quit his job began in June, when he traveled to Arizona to take his son to college. He was told he would need to complete a 14-day unpaid quarantine after the trip and would need back-to-back negative novel coronavirus tests before he could return to work.

When he went to get the second test, Garcia said, his doctor told him he was risking his life by continuing to work in the prison because he has diabetes.

He requested an extension on his medical leave under a provision in the federal CARES Act for people at risk of developing a severe case of COVID-19. But he said his application was denied.

"I felt like they turned their backs on me," he said.

Many of his colleagues were already using medical leave to get a break from a grueling work schedule that, due to a massive staffing shortage, included regular mandatory overtime, he said, adding it was "the only way to get a break when you are working 16 to 20 hours a day."

When Garcia's medical leave ran out, his wife and kids begged him not to go back, and he agreed.

"It's too dangerous," Garcia said. "I still have things I want to do."

James Carter, 38, said he worked at the Los Lunas prison for 16 years before quitting in September.

He volunteered to work in the prison's COVID-19 unit, which initially had only one patient. As more prisoners tested positive for the virus and the prison began quarantining incoming inmates, he said, the administration began housing both infected inmates and new prisoners in the same unit.

The men were in separate cells, Carter said, but they all shared a common ventilation system.

Carter said the quarantining inmates were restless because they only were allowed out of the cell once a day to shower. They couldn't make phone calls and weren't allowed to receive mail.

"They had no clue what was going on," he said. "I would do what I could to learn what was going on to keep them calm."

Carter also complained that prison officials never taught the guards how to decontaminate themselves at the end of a shift.

"We had a can of Lysol, and we would line up and spray each other down with Lysol," he said.

The first outbreak Carter was aware of came in July. A nurse who worked in both the COVID-19 unit and the main infirmary tested positive, he said.

"So they tested everyone, and I came out positive, too," he said.

Carter said he was placed on paid leave and told to quarantine until he could produce back-to-back negative tests. He was cleared to work "two months and 18 tests later," he said.

Shortly after he returned, he became ill and was diagnosed with a strep infection that required hospitalization.

When he recovered, the prison wanted him to take another COVID-19 test.

"It would have been the sixth time in a one-week period," he said. "I said, 'I'm not going to test again.' If you refuse to get tested, they send you home on your own leave time."

He resigned.

Harrison didn't provide responses to questions about prison workers' morale or the pandemic's effects on staffing shortages.

In an email, he said, "We are grateful for our dedicated staff that continue to show up to work each day to combat the virus and maintain public safety."

Read this article:
Virus cases are on the rise in state prisons - taosnews

New York, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Primary Cells Market Research Report by Origin, by Cell Type, by End-user - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05987887/?utm_source=GNW

The Global Primary Cells Market is expected to grow from USD 925.79 Million in 2019 to USD 1,733.95 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 11.02%.

Market Segmentation & Coverage: This research report categorizes the Primary Cells to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Origin, the Primary Cells Market studied across Animal Primary Cells and Human Primary Cells.

Based on Cell Type, the Primary Cells Market studied across Dermatocytes, Gastrointestinal Cells, Heart Cells, Hematopoietic Cells, Hepatocytes, Lung Cells, Musculoskeletal Cells, and Renal Cells. The Hepatocytes further studied across Cryopreserved Hepatocytes and Fresh Hepatocytes.

Based on End-user, the Primary Cells Market studied across Life Science Companies and Research Institutes.

Based on Geography, the Primary Cells Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles: The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Primary Cells Market including AcceGen, Allcells, American Type Culture Collection, Axol Bioscience Ltd., BioIVT, Biopredic International, BPS Bioscience, Inc., Cell Biologics, Inc., Corning Incorporated, Creative Bioarray, Epithelix SRL, Ixcells Biotechnologies, Lonza Group AG, Merck KGaA, Neuromics, Ppa Research Group, Inc., Promocell GmbH, Reachbio LLC, Sciencell Research Laboratories, Inc., Sekisui Xenotech, LLC, Stem Cell Technologies, Inc., StemExpress, LLC, Thermo Fisher Scientific, Inc., and Zenbio, Inc..

FPNV Positioning Matrix: The FPNV Positioning Matrix evaluates and categorizes the vendors in the Primary Cells Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window: The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19: COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers: 1. Market Penetration: Provides comprehensive information on the market offered by the key players 2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as: 1. What is the market size and forecast of the Global Primary Cells Market? 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Primary Cells Market during the forecast period? 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Primary Cells Market? 4. What is the competitive strategic window for opportunities in the Global Primary Cells Market? 5. What are the technology trends and regulatory frameworks in the Global Primary Cells Market? 6. What are the modes and strategic moves considered suitable for entering the Global Primary Cells Market?Read the full report: https://www.reportlinker.com/p05987887/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Continued here:
Primary Cells Market Research Report by Origin, by Cell Type, by End-user - Global Forecast to 2025 - Cumulative Impact of COVID-19 - GlobeNewswire

MarketsandResearch.biz presents Global Cell and Gene Therapy Market 2020 by Company, Regions, Type and Application, Forecast to 2025 which shows the most recent industry chain structure and complete analysis of the market. The report offers detailed information on enterprises on a global and regional level through an all-inclusive analysis and insights into developments affecting businesses. The report covers the market landscape and its growth prospects over the coming years. Leading companies effective in this market are discussed further. The report calculates the market size and considers the revenue generated from the sales of Cell and Gene Therapy globally. The research accommodates an entire overview of the market, including the market share, and the projection of this global market, within a specific interval of time.

The report contains critical information on the market which will assist the industry players in making informed business move. The report is segmented by application/ end-user, product type, and geologies. This report will help you to make informed decisions, understand opportunities, plan new projects, analyze drivers and restraints, and give you a vision of the industry forecast (2020-2025). The report further explains the competitive backdrop of key players in the market as well as their product portfolio and business strategies. It offers an investigation of the global Cell and Gene Therapy industry in terms of consumption and production.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/110107

NOTE: Our report highlights the major issues and hazards that companies might come across due to the unprecedented outbreak of COVID-19.

Market Status:

The market report provides the major growth factors and limitations that notably affect market growth. The report studies the data about the past and present status of the global Cell and Gene Therapy market globally. The upcoming economic fluctuations related to the current market growth pattern of the market are investigated. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

The market competition by top manufacturers/key player profiled: Amgen Inc., Novartis AG, Fibrocell Science, Inc., bluebird bio, Inc., Kolon TissueGene, Inc., Dendreon Pharmaceuticals LLC., Organogenesis Holdings Inc., Kite Pharma, Inc., Human Stem Cells Institute, Orchard Therapeutics plc., Spark Therapeutics, Inc., Pfizer, Inc., Vericel Corporation, Sibiono GeneTech Co. Ltd.,, RENOVA THERAPEUTICS, ViroMed Co., Ltd., Shanghai Sunway Biotech Co., Ltd.,

The report conjointly categorizes the market into main product kind: Rare Diseases, Oncology, Hematology, Cardiovascular, Ophthalmology, Neurology, Other Therapeutic Classes

The report splits the market into main applications: Pharmaceutical and Biotechnology Companies, Research and Academic Institutions, Contract Research Organizations (CROs), Hospital, Others

The report offers an in-depth assessment of the growth and other aspects of the market in important regions, including: North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), Middle East & Africa (Saudi Arabia, UAE, Egypt and South Africa)

The conclusion contains the evaluation of the global Cell and Gene Therapy market through multiple classifications and provides thorough information about the upstream raw materials, downstream buyers, and distribution channels established by the various competitors. More importantly, a study of recent market trends, drivers, challenges, and opportunities shaping the profitability graph of the industry are presented further in the report.

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/110107/global-cell-and-gene-therapy-market-2020-by-company-regions-type-and-application-forecast-to-2025

Key Pointers:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.marketsandresearch.biz

Visit link:
Global Cell and Gene Therapy Market 2020 Key Drivers and Challenges, Opportunities and Forecast Insights by 2025 - KYT24